Shahid F and Lip GY. Risk stratification models in atrial fibrillation. Semin Thromb Hemost. Epub ahead of print 27 January 2017. DOI: 10.1055/s-0036-1597285.
2.
FolsomARNambiVBellEJ. Troponin T, N-terminal pro-B-type natriuretic peptide, and incidence of stroke: The Atherosclerosis Risk in Communities Study. Stroke2013; 44: 961–967.
3.
BerntssonJZiaEBorneY. Plasma natriuretic peptides and incidence of subtypes of ischemic stroke. Cerebrovasc Dis2014; 37: 444–450.
4.
MandalenakisZErikssonHWelinL. Atrial natriuretic peptide as a predictor of atrial fibrillation in a male population study. The Study of Men Born in 1913 and 1923. Int J Cardiol2014; 171: 44–48.
5.
PastormerloLEMaffeiSLattaDD. N-terminal prob-type natriuretic peptide is a marker of vascular remodelling and subclinical atherosclerosis in asymptomatic hypertensives. Eur J Prev Cardiol2016; 23: 366–376.
6.
LindbergSJensenJSPedersenSH. MR-proANP improves prediction of mortality and cardiovascular events in patients with stemi. Eur J Prev Cardiol2015; 22: 693–700.
7.
KatanMFluriFSchuetzP. Midregional pro-atrial natriuretic peptide and outcome in patients with acute ischemic stroke. J Am Coll Cardiol2010; 56(13): 1045–1053.
8.
Berntsson J, Smith JG, Peter Nilsson M, et al. Pro-atrial natriuretic peptide and prediction of atrial fibrillation and stroke: The Malmö Preventive Project. Eur J Prev Cardiol. 2017; 24: 788–795.
Newton-ChehCLarsonMGVasanRS. Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure. Nat Genet2009; 41: 348–353.
11.
LevyDHwangSJKayalarA. Associations of plasma natriuretic peptide, adrenomedullin, and homocysteine levels with alterations in arterial stiffness: The Framingham Heart Study. Circulation2007; 115: 3079–3085.
12.
RubattuSStanzioneRDi AngelantonioE. Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke2004; 35: 814–818.
13.
PonikowskiPVoorsAAAnkerSD. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J2016; 37(27): 2129–2200.
14.
SmithJGPlatonovPGHedbladB. Atrial fibrillation in the Malmo Diet and Cancer Study: A study of occurrence, risk factors and diagnostic validity. Eur J Epidemiol2010; 25: 95–102.
15.
HanZJWuXDChengJJ. Diagnostic accuracy of natriuretic peptides for heart failure in patients with pleural effusion: A systematic review and updated meta-analysis. PLoS One2015; 10: e0134376–e0134376.
16.
KatanMMoonYvon EckardsteinA. Procalcitonin and midregional proatrial natriuretic peptide as biomarkers of subclinical cerebrovascular damage: The Northern Manhattan Study. Stroke2017; 48: 604–610.
17.
KubeJEbnerNJankowskaEA. The influence of confounders in the analysis of mid-regional pro-atrial natriuretic peptide in patients with chronic heart failure. Int J Cardiol2016; 219: 84–91.
18.
ZabarovskajaSHageCLindeC. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes. Int J Cardiol2015; 189: 6–11.
19.
KlugGFeistritzerHJReinstadlerSJ. Association of aortic stiffness with biomarkers of myocardial wall stress after myocardial infarction. Int J Cardiol2014; 173(2): 253–258.
20.
Funke-KaiserAHavulinnaASZellerT. Predictive value of midregional pro-adrenomedullin compared to natriuretic peptides for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort. Ann Med2014; 46(3): 155–162.
21.
FischerMKatanMMorgenthalerNG. The prognostic value of midregional proatrial natriuretic peptide in patients with hemorrhagic stroke. Cerebrovasc Dis2014; 37(2): 128–133.
22.
TzikasSKellerTOjedaFM. MR-proANP and MR-proADM for risk stratification of patients with acute chest pain. Heart2013; 99(6): 388–395.
